Aspen Secures Approval to Market Lilly’s Mounjaro for Weight Loss in South Africa

Aspen Pharmacare announced that it has obtained regulatory approval in South Africa to market Lilly’s Mounjaro (tirzepatide) for chronic weight management, expanding the indication beyond its prior authorization for Type 2 diabetes. 

Background & Strategic Rationale

• Aspen had previously launched Mounjaro in South Africa in December 2024 under a diabetes indication. 

• With this new approval, Aspen will market Mounjaro using a KwikPen injector device, facilitating self-administration. 

• The move positions Aspen to compete more directly with Novo Nordisk’s Wegovy, which entered the South African weight-loss market in August 2025 — about eight months after Lilly’s original diabetes launch. 

• The South African Health Products Regulatory Authority (SAHPRA) granted this new approval, allowing Aspen to tap into the rapidly growing obesity treatment market, estimated to exceed USD 100 billion globally by decade’s end. 

Implications & Challenges 

1. Expanded Indication Offers Growth Potential

   With obesity and weight-management drugs commanding growing market attention, the new label broadens the addressable patient base beyond diabetics.

2. Market Competition Intensifies

   Direct competition with established weight-loss therapies (e.g. Wegovy) will require strong differentiation, patient support, and pricing strategies.

3. Regulatory & Access Considerations

   Approval is just the first step — reimbursement decisions, clinical guidelines, and safety monitoring (especially long-term) will influence uptake.

4. Operational Readiness

   Aspen must ensure supply chain robustness, quality assurance, and post-market surveillance as it scales weight-loss usage.

5. Pricing & Market Access

   In many markets, weight-management treatments face scrutiny over cost, payer coverage, and whether such therapies are considered essential or elective.